Abstract:Background Type 1 diabetes mellitus (T1DM) is caused by immune cell-mediated β-cell dysfunction. In recent decades, N6-methyladenosine (m6A) has attracted widespread attention in the scientific research field because it plays vital roles in the pathogenesis of immunity-related diseases, including autoimmune diseases. However, neither the m6A modification profile nor the potential role it plays in T1DM pathogenesis has been investigated to date. Materials and Methods An m6A mRNA epitranscriptomic microarray analysis was performed to analyze m6A regulator expression patterns and m6A methylation patterns in immune cells of T1DM patients (n=6) and healthy individuals (n=6). A bioinformatics analysis was subsequently performed to explore the potential biological functions and signaling pathways underlying T1DM pathogenesis. Furthermore, mRNA expression and m6A methylation levels were subsequently verified by qRT–PCR and methylated RNA immunoprecipitation–qPCR (MeRIP–qPCR), respectively, in the T1DM and healthy groups (n=6 per group). Results Among the multiple m6A regulators, METTL3 and IGF2BP2 had significantly downregulated expression, and YTHDC1 and HNRNPA2B1 had significantly upregulated expression in the T1DM group relative to the healthy group. The microarray analysis revealed 4247 differentially methylated transcripts, including 932 hypermethylated and 3315 hypomethylated transcripts, and 4264 differentially expressed transcripts, including 1818 upregulated transcripts and 2446 downregulated transcripts in the T1DM group relative to the healthy group. An association analysis between methylation and gene expression demonstrated that the expression of 590 hypermethylated transcripts was upregulated, and that of 1890 hypomethylated transcripts was downregulated. Pearson correlation analysis showed significant correlations between the expression levels of differentially expressed m6A regulators and the methylation levels of differentially methylated transcripts and significant correlations between the expression levels of differentially expressed m6A regulators and that of differentially expressed transcripts. Moreover, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses demonstrated that differentially methylated transcripts were involved in pathways related to immunity, including some closely associated with T1DM. Conclusions Our study presents m6A regulator expression patterns and m6A methylation patterns of immune cells in T1DM, showing that the m6A mark and m6A regulators are promising targets for T1DM diagnosis and treatment.

Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5.

DecreasedN6-Methyladenosine in Peripheral Blood RNA from Diabetic Patients is Associated WithFTOExpression Rather ThanALKBH5

N6-Methyladenosine Demethylase FTO Controlsmacrophage Homeostasis in Diabetic Vasculopathy

Glucose Is Involved in the Dynamic Regulation of m6A in Patients With Type 2 Diabetes.

Comprehensive analysis of the m6A demethylase FTO in endothelial dysfunction by MeRIP sequencing

Hyperglycemia affects global 5-methylcytosine and 5-hydroxymethylcytosine in blood genomic DNA through upregulation of SIRT6 and TETs

N6-methyladenosine demethylase fat mass and obesity-associated protein suppresses hyperglycemia-induced endothelial cell injury by inhibiting reactive oxygen species formation via autophagy promotion

The role of m 6 A modification in type 2 diabetes: a systematic review and integrative analysis

U‐shaped Association Between Serum IGF2BP3 and T2DM: A Cross‐sectional Study in Chinese Population

Changes of m6A Regulatory Proteins and Nrf2 Signaling Molecules in Liver Tissue of Type 2 Diabetes Mellitus Rats

FTO regulates adipogenesis by controlling cell cycle progression via mA-YTHDF2 dependent mechanism.

N 6-Methyladenosine demethylase FTO controls macrophage homeostasis in diabetic vasculopathy

Increased N6-Methyladenosine Causes Infertility Is Associated With Fto Expression

Changes in N6-Methyladenosine Modification Modulate Diabetic Cardiomyopathy by Reducing Myocardial Fibrosis and Myocyte Hypertrophy

Association of FTO gene methylation with incident type 2 diabetes mellitus: A nested case–control study

FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms

Association of FTO Methylation Level with Incident Type 2 Diabetes Mellitus: a Nested Case–control Study Within the Rural Chinese Cohort Study

Effect of demethyltransferase FTO on tumor progression

Author Correction: NADP Modulates RNA M6a Methylation and Adipogenesis Via Enhancing FTO Activity

The m6A methylation profiles of immune cells in type 1 diabetes mellitus

��清igf2bp3与2型糖尿病的u型关联:一项中国人群横断面研究